pmc logo image
Logo of canvetjReference to the Publisher site.Journal Web siteJournal Web siteHow to Submit

Formats:

Can Vet J. 2000 April; 41(4): 296–300.
PMCID: PMC1476158
Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis.
P A Doig, K A Purbrick, J E Hare, and D B McKeown
Boehringer Ingelheim Vetmedica, Burlington, Ontario, Canada.
Abstract
A clinical trial was conducted to evaluate the safety and efficacy of the nonsteroidal anti-inflammatory drug meloxicam in dogs with chronic osteoarthritis. Forty clinical cases were enrolled in the 2-phase study. Phase 1 compared therapeutic efficacy and tolerance of meloxicam or placebo for 1 week. Phase 2 involved a 4-week evaluation of the drug's clinical efficacy and tolerance. Clinical efficacy was evaluated by using a scoring system that assessed specific lameness, general stiffness, painful rise, exercise intolerance, and behavior. Evaluations demonstrated significant reductions (P < 0.05) in clinical signs of osteoarthritis following 4 weeks of drug therapy. Side effects were minimal in extent and duration. The drug was accepted without problems in the majority of cases. The findings of this investigation suggest that the efficacy, tolerance, and formulation of meloxicam oral suspension make it well suited for the treatment of chronic osteoarthritis in the dog.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Images in this article
Click on the image to see a larger version.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Engelhardt G, Bögel R, Schnitzer C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings. Biochem Pharmacol. 1996 Jan 12;51(1):21–28. [PubMed]
  • Engelhardt G, Bögel R, Schnitzler C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem Pharmacol. 1996 Jan 12;51(1):29–38. [PubMed]
  • Hansen B, Hardie E. Prescription and use of analgesics in dogs and cats in a veterinary teaching hospital: 258 cases (1983-1989). J Am Vet Med Assoc. 1993 May 1;202(9):1485–1494. [PubMed]
  • Mathews KA. Nonsteroidal anti-inflammatory analgesics in pain management in dogs and cats. Can Vet J. 1996 Sep;37(9):539–545. [PubMed]
  • Engelhardt G, Bögel R, Schnitzler C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem Pharmacol. 1996 Jan 12;51(1):29–38. [PubMed]
  • Van Bree H, Justus C, Quirke JF. Preliminary observations on the effects of meloxicam in a new model for acute intra-articular inflammation in dogs. Vet Res Commun. 1994;18(3):217–224. [PubMed]
  • Cross AR, Budsberg SC, Keefe TJ. Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs. Am J Vet Res. 1997 Jun;58(6):626–631. [PubMed]
  • Wallace JL. NSAID gastroenteropathy: past, present and future. Can J Gastroenterol. 1996 Nov–Dec;10(7):451–459. [PubMed]
  • Masferrer JL, Isakson PC, Seibert K. Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am. 1996 Jun;25(2):363–372. [PubMed]
  • Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res. 1995 Oct;44(10):423–433. [PubMed]